The U.S. Food and Drug Administration (FDA) recently approved a new medication called Zoryve foam. It’s a steroid-free treatment used once a day for plaque psoriasis, a skin condition that causes itchy, scaly patches on the scalp and body. This good news for many also reminds us why it’s so important for Black Americans to be part of the medical studies that test new drugs.
Zoryve (whose chemical name is roflumilast) is a 0.3 percent foam, approved for adults and kids 12 years and older to treat plaque psoriasis. This approval is a big step because it offers a new option that doesn’t contain steroids, which can have side effects if used for a long time.
The FDA based its decision on two main studies: the ARRECTOR phase 3 clinical trial and Trial 204 (a phase 2 clinical trial). Together, these studies included 736 adults and teenagers with psoriasis that ranged from mild to serious. In the studies, some people got Zoryve foam, and others got a “vehicle foam” – that’s a similar foam but without the actual medicine. This helps researchers see if the real drug works better. Everyone used their assigned foam once a day for eight weeks.
To see how well Zoryve worked, doctors used a scale called the Investigator Global Assessment (IGA). This scale helps them judge if the psoriasis got “clear” or “almost clear” and improved by at least two steps from how it looked at the start.
In the ARRECTOR study, many more people using Zoryve saw good results compared to those using the plain foam. For scalp psoriasis, 66.4 percent of Zoryve users had success, versus only 27.8 percent of vehicle foam users. For body psoriasis, 45.5 percent of Zoryve users had success, compared to 20.1 percent of vehicle users. The results from Trial 204 were similar, showing Zoryve worked much better than the foam without medicine.
Dr. Jennifer Soung, a dermatologist and one of the researchers in the trials, said, “In clinical trials, Zoryve foam not only effectively cleared psoriasis plaques on the body and scalp, but also provided rapid itch relief.” She added that Zoryve “can be safely used for any duration and offers two highly convenient formulations, cream or foam… Zoryve foam allows patients to treat their whole body with one prescription, transforming the treatment landscape for scalp and body psoriasis.” Arcutis Biotherapeutics is the company that got Zoryve approved.
Why Black American Participation in Clinical Trials is Important
While Zoryve is a positive step, we also need to think about who participates in the studies that test these new drugs. Psoriasis affects people of all backgrounds, but it can look different and respond differently to treatment in various racial and ethnic groups.
For Black Americans, psoriasis might not always look like the typical red, scaly patches seen in textbooks. Instead, our patches might be a darker purple or grayish color, or cause more noticeable changes in skin color (darker or lighter spots) even after the psoriasis clears. This can sometimes make it harder to get the right diagnosis quickly.
Unfortunately, we have often been underrepresented in clinical trials – the studies that test new medicines. This lack of representation is a serious problem for several reasons:
-
Does it Work the Same for Everyone? If a drug is mostly tested on one group of people (like white patients), doctors can’t be sure it will work as well or have the same side effects for Black patients. Small differences in our bodies, sometimes due to our genes or environment, can change how a medicine works. Without enough Black participants in studies for drugs like Zoryve, it’s harder to know exactly how it will help them.
-
Understanding Psoriasis Better: When studies include people from all backgrounds, researchers learn more about how psoriasis affects different groups. This can lead to better ways to diagnose and treat the condition for everyone.
-
Fairness in Health Care: Everyone deserves the best medical care. Black Americans sometimes face more health problems or have a harder time getting quality care. Making sure they are included in clinical trials is a key step toward making health care fairer and ensuring new treatments work well for them.
-
Finding Different Side Effects: Just like a medicine might work differently, it might also cause different side effects in different groups of people. If Black Americans aren’t well represented in trials, specific side effects that might affect them more could be missed.
Many things can make it harder for Black Americans to join clinical trials. Sometimes it’s a lack of trust in the medical system because of past unfair treatment. Other times, people might not know about trials, or things like transportation and time off work can be barriers.
To fix this, drug companies, doctors, and community groups need to work together. They need to build trust, make sure people know about trial opportunities, and make it easier to participate.
The approval of Zoryve is good news for people with psoriasis. But it also highlights why we must keep working to include more Black Americans in medical research. When clinical trials truly represent everyone, we can be more confident that new treatments will be safe and effective for all who need them. This is how we make sure medical progress benefits everyone in our diverse communities.
